PARACETAMOL Carelide 10mg/ml (1000mg/100ml) Infusion/Solution for

What is PARACETAMOL Carelide 10mg/ml (1000mg/100ml)

PARACETAMOL Carelide 10 mg/ml is a sterile intravenous infusion solution containing 1 g of paracetamol (acetaminophen) in a 100 ml bag at a concentration of 10 mg/ml. Supplied in packs of 50 for hospital and clinical use, it provides fast-acting analgesic and antipyretic effects when oral administration isn’t feasible—such as post-surgery, in emergency settings, or for patients unable to swallow or tolerate oral medications.

• Formulation: 100 ml intravenous infusion bag (plastic), 1 g dose
• Active Compound: Paracetamol (Acetaminophen), 10 mg/ml
• Therapeutic Category: Non-opioid analgesic and antipyretic
• Indications: Mild to moderate pain; fever reduction when oral route is unsuitable :contentReference[oaicite:1]{index=1}
• Target Users: Adults, adolescents, and children (weight-based dosing), administered under medical supervision

This IV form achieves peak plasma levels rapidly—typically within 8–15 minutes—making it effective for acute pain and fever control :contentReference[oaicite:2]{index=2}.

How to use PARACETAMOL Carelide 10mg/ml (1000mg/100ml)

Administration must be performed by trained healthcare professionals following standard aseptic and infusion guidelines.

• Inspect bag: Ensure solution is clear, colorless, and particle-free. Discard if compromised :contentReference[oaicite:3]{index=3}.
• Infusion: Administer over at least 15 minutes via a dedicated IV line; rapid bolus is contraindicated :contentReference[oaicite:4]{index=4}.
• Frequency: Typically every 4–6 hours per dosage guidelines below.
• Compatibility: Do not mix with other medications unless compatibility is confirmed :contentReference[oaicite:5]{index=5}.
• Single-use: Dispose of unused solution immediately after infusion.
• Monitoring: Observe vital signs during administration and assess pain reduction and temperature response.

A volumetric pump is preferred to ensure precise infusion volume and timing :contentReference[oaicite:6]{index=6}.

Mode of Action PARACETAMOL Carelide 10mg/ml (1000mg/100ml)

Though its precise mechanism is not fully understood, paracetamol’s analgesic and antipyretic actions are well described:

• CNS COX Inhibition: Paracetamol reversibly inhibits central cyclooxygenase enzymes (COX‑2/COX‑3), reducing prostaglandin synthesis associated with pain and fever :contentReference[oaicite:7]{index=7}.
• Thermoregulation: Acts on the hypothalamic center to increase heat loss via vasodilation, thus lowering fever :contentReference[oaicite:8]{index=8}.
• Neuronal Modulation: Potential activation of serotonergic and endocannabinoid pathways and metabolite AM404, enhancing descending inhibitory pain mechanisms :contentReference[oaicite:9]{index=9}.
• Limited Peripheral Effect: Minimal anti-inflammatory activity in peripheral tissues, preserving gastric and platelet integrity :contentReference[oaicite:10]{index=10}.

IV administration ensures rapid systemic availability, with effects noted within 5–15 minutes :contentReference[oaicite:11]{index=11}.

PARACETAMOL Carelide 10mg/ml (1000mg/100ml) Interactions PARACETAMOL Carelide 10mg/ml (1000mg/100ml)

Paracetamol has a generally favorable interaction profile, but caution is warranted with:

• Enzyme inducers: Drugs like carbamazepine, phenytoin, and rifampicin increase CYP pathway activity, leading to higher levels of toxic metabolite NAPQI :contentReference[oaicite:12]{index=12}.
• Isoniazid: May elevate hepatotoxic risk through reduced detoxification capacity :contentReference[oaicite:13]{index=13}.
• Warfarin/Anticoagulants: Chronic high-dose use may enhance anticoagulant effect; INR monitoring is advised :contentReference[oaicite:14]{index=14}.
• Lonafarnib: Serious interaction via CYP3A4—avoid concurrent use :contentReference[oaicite:15]{index=15}.
• Other CYP3A4 substrates: Caution warranted with drugs like tacrolimus, imatinib, etc.—monitor for increased effects :contentReference[oaicite:16]{index=16}.
• Alcohol: Chronic consumption depletes glutathione, increasing risk of hepatotoxicity :contentReference[oaicite:17]{index=17}.

Overall, inform healthcare providers of all medications and alcohol use to prevent adverse interactions.

Dosage of PARACETAMOL Carelide 10mg/ml (1000mg/100ml)

Dosing must follow weight, age, and renal/hepatic status:

• Adults & Adolescents ≥50 kg: 1 g (100 ml) every 4–6 hours; max 4 g/day (3 g/day if hepatic risk factors present) :contentReference[oaicite:18]{index=18}.
• Children 10–50 kg: 15 mg/kg per dose every 4–6 hours; max 60 mg/kg/day (≤3 g/day) :contentReference[oaicite:19]{index=19}.
• Infants <10 kg: 7.5–10 mg/kg every 6–8 hours; max 30 mg/kg/day :contentReference[oaicite:20]{index=20}.
• Renal/hepatic impairment: Extend dosing interval or reduce total daily dose; contraindicated in severe hepatic disease :contentReference[oaicite:21]{index=21}.

Each infusion should take at least 15 minutes; dose precisely in mg and ml to avoid 10-fold overdose :contentReference[oaicite:22]{index=22}.

Possible side effects of PARACETAMOL Carelide 10mg/ml (1000mg/100ml)

IV paracetamol is well tolerated, but adverse effects may include:

• Common: Infusion-site pain, headache, nausea, flushing, mild transient hypotension :contentReference[oaicite:23]{index=23}.
• Laboratory changes: Mild elevation of liver enzymes during prolonged use :contentReference[oaicite:24]{index=24}.
• Rare/Serious: Anaphylaxis, bronchospasm, serious skin reactions (e.g. SJS/TEN), liver damage in overdose, blood disorders like thrombocytopenia or neutropenia :contentReference[oaicite:25]{index=25}.

Monitor vital signs during infusion and consider periodic liver function tests when infusions continue over several days.

PARACETAMOL Carelide 10mg/ml (1000mg/100ml) Contraindications PARACETAMOL Carelide 10mg/ml (1000mg/100ml)

Do not administer in the following scenarios:

• Hypersensitivity: Known allergy to paracetamol or any bag components :contentReference[oaicite:26]{index=26}.
• Severe hepatic impairment: Active liver disease or decompensated cirrhosis :contentReference[oaicite:27]{index=27}.
• Severe renal insufficiency: Creatinine clearance <30 ml/min—use with caution :contentReference[oaicite:28]{index=28}.
• Chronic alcoholism/malnutrition: Higher risk of glutathione depletion and hepatotoxicity :contentReference[oaicite:29]{index=29}.
• Concurrent hepatotoxic medications: Avoid alongside other drugs metabolized through similar pathways :contentReference[oaicite:30]{index=30}.

For pediatric patients under 2, consult pediatric specialists as per guidance :contentReference[oaicite:31]{index=31}.

Storage of PARACETAMOL Carelide 10mg/ml (1000mg/100ml)

Maintain quality and safety through appropriate storage and handling:

• Temperature: Store between 15–25 °C; do not freeze :contentReference[oaicite:32]{index=32}.
• Light protection: Keep bags in original cartons to guard against light.
• Visual inspection: Check clarity and absence of particulate matter before use; discard compromised bags :contentReference[oaicite:33]{index=33}.
• Single-use: Discard any unused portion to prevent contamination.
• Expiry: Do not use past the printed expiration date.
• Disposal: Follow institutional protocols for clinical waste disposal.